Special Issue

Novel Therapeutic Considerations in Bone and Soft Tissue Sarcoma

Message from the Guest Editors

Sarcomas are a group of rare cancers that arise in connective tissues of the body. These tumours exhibit a wide range of differing behaviours and underlying molecular pathologies. The two main types of sarcoma are soft tissue and bone sarcomas, but there are more than 70 different entities within these two categories. There is limited medical understanding of this type of rare malignancy. The natural history of these aggressive tumours is characterized by a strong tendency toward local recurrence and metastatic spreading. Despite advances in the rapeutic approaches over the last several decades, the outcome for metastatic patients remains poor. Therefore, it is important to identify patients who are at high risk for tumour recurrence and dissemination, which has resulted in an increasing interest in the investigation of prognostic biomarkers that help to guide treatment decisions. In this Special Issue we will present original research and review articles highlighting novel therapeutic approaches in the treatment of sarcoma patients.

Guest Editors

Dr. Joanna Szkandera

Division of Oncology, Medical University of Graz, 8036 Graz, Austria

Dr. Dimosthenis Andreou

Division of Orthopedic Oncology and Sarcoma Surgery, Helios Hospital Bad Saarow, Sarcoma Center Berlin-Brandenburg, 15526 Bad Saarow, Germany

Deadline for manuscript submissions

closed (30 June 2021)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/39442

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

